Influenza, Updated COVID-19, and Respiratory Syncytial Virus Vaccination Coverage Among Adults - United States, Fall 2023.
Level 4 - case-series / case-control
Cross-sectional telephone survey
PubMed 38127675 · doi:10.15585/mmwr.mm7251a4
What was done
Data from the National Immunization Survey-Adult COVID Module, a random-digit-dialed cellular telephone survey of United States adults aged 18 years and older, were analyzed to evaluate coverage and intent for influenza, updated 2023–2024 COVID-19, and respiratory syncytial virus (RSV) vaccines as of December 9, 2023.
What was found
By December 9, 2023, an estimated 42.2% of adults aged ≥18 years had received an influenza vaccine and 18.3% had received an updated COVID-19 vaccine. Among adults aged ≥60 years, 17.0% had received an RSV vaccine. Additionally, approximately 27% and 41% of adults aged ≥18 years and 53% of adults aged ≥60 years reported that they definitely or probably will be vaccinated or were unsure whether they would be vaccinated against influenza, COVID-19, and RSV, respectively. Coverage varied by demographic characteristics.
Why it matters
This report establishes early-season national benchmarks for the simultaneous rollout of three adult respiratory vaccines in fall 2023, identifying low uptake for updated COVID-19 and RSV vaccines despite public health recommendations.
Limits
The sample size is not reported in the abstract. All vaccination metrics rely on self-reported data without clinical verification, introducing recall and social desirability biases, and random-digit-dialed cellular surveys are susceptible to nonresponse bias.
Cited by
- supports Current pediatric COVID-19 vaccination rates in the US are around 10%, pediatric flu vaccination rates are around 50%, and adult COVID-19 vaccination rates are around 20%.